Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreu Vilaseca-Jolonch

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Medical Economics|August 12, 2022
Evaluating the cost-utility of a direct transfer to angiosuite protocol within 6 h of symptom onset in suspected large vessel occlusion patientsManuel Requena, Valeska Seguel-Ravest, Andreu Vilaseca-Jolonch, et al.
Epilepsy & Behavior : E&B|July 24, 2020
Tumor-associated status epilepticus: A prospective cohort in a tertiary hospitalAndreu Vilaseca-Jolonch, Laura Abraira, Manuel Quintana, et al.
Journal of Neuroimmunology|March 7, 2026
Morvan syndrome associated with prominent Tau pathology: A clinicopathological case reportGary Álvarez Bravo, Rosa Ferrer Tarrés, Andreu Vilaseca Jolonch, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2023
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosisNicolás Fissolo, Pascal Benkert, Jaume Sastre-Garriga, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 24, 2026
Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progressionAlvaro Cobo-Calvo, Juan Pablo Cuello, Enric Monreal, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 12, 2025
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysisAhmed Abdelhak, Franziska Bachhuber, Kiarra Ning, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Medical Economics|August 12, 2022
Evaluating the cost-utility of a direct transfer to angiosuite protocol within 6 h of symptom onset in suspected large vessel occlusion patientsManuel Requena, Valeska Seguel-Ravest, Andreu Vilaseca-Jolonch, et al.
Epilepsy & Behavior : E&B|July 24, 2020
Tumor-associated status epilepticus: A prospective cohort in a tertiary hospitalAndreu Vilaseca-Jolonch, Laura Abraira, Manuel Quintana, et al.
Journal of Neuroimmunology|March 7, 2026
Morvan syndrome associated with prominent Tau pathology: A clinicopathological case reportGary Álvarez Bravo, Rosa Ferrer Tarrés, Andreu Vilaseca Jolonch, et al.
European Journal of Neurology|January 30, 2026
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple SclerosisNicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2023
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosisNicolás Fissolo, Pascal Benkert, Jaume Sastre-Garriga, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 24, 2026
Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progressionAlvaro Cobo-Calvo, Juan Pablo Cuello, Enric Monreal, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 12, 2025
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysisAhmed Abdelhak, Franziska Bachhuber, Kiarra Ning, et al.
Pageof 1